EPI-MIGRANT
Identification of epigenetic markers underlying increased risk of T2D in South Asians
| Coordinatore | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.epimigrant.eu |
| Totale costo | 3˙903˙100 € |
| EC contributo | 2˙999˙052 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP-SICA |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-12-01 - 2014-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | coordinator | 717˙908.60 |
| 2 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 988˙054.00 |
| 3 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | participant | 591˙600.00 |
| 4 |
DEVKI DEVI FOUNDATION SOCIETY
Organization address
address: PRESS ENCLAVE ROAD SAKET 2 contact info |
IN (NEW DELHI) | participant | 360˙024.00 |
| 5 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | participant | 102˙012.00 |
| 6 |
OULUN YLIOPISTO
Organization address
address: Pentti Kaiteran Katu 1 contact info |
FI (OULU) | participant | 89˙378.40 |
| 7 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 64˙794.00 |
| 8 |
BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED
Organization address
address: COMMERCIAL ROAD 75 VICTORIA contact info |
AU (MELBOURNE) | participant | 62˙928.00 |
| 9 |
NATIONAL UNIVERSITY OF SINGAPORE
Organization address
address: LOWER KENT RIDGE ROAD 21 contact info |
SG (SINGAPORE) | participant | 7˙353.00 |
| 10 |
UNIVERSITY OF KELANIYA
Organization address
address: DALUGAMA contact info |
LK (KELANIYA) | participant | 6˙300.00 |
| 11 |
UNIVERSITY OF MAURITIUS
Organization address
address: Reduit contact info |
MU (REDUIT) | participant | 6˙300.00 |
| 12 |
CELLCENTRIC LIMITED
Organization address
address: "CHESTERFORD RESEARCH PARK, LITTLE CHESTERFORD" contact info |
UK (CAMBRIDGE) | participant | 2˙400.00 |
| 13 |
National Center for Global Health and Medicine
Organization address
address: Toyama 1-21-1 contact info |
JP (Tokyo) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This project focuses on identification of epigenetic risk factors underlying the increased rates of type-2 diabetes (T2D) amongst South Asians in their home countries, migrants to Europe and other parts of the world. Known environmental and genetic factors explain only a small part of the increased risk of T2D among South Asians, who constitute the highest numbers of people with T2D worldwide.
We hypothesise that epigenetic modification contributes to the increased T2D risk amongst South Asians. We will carry out an epigenome-wide scan of DNA methylation in whole blood, among T2D cases and controls from non-migrant (living in India or Pakistan) and migrant (living in the UK) South Asians. Further testing of top-ranking markers will be carried out in South Asian T2D cases and controls from UK, India, Mauritius, Pakistan, Singapore and Sri Lanka. We will use results to investigate the mechanisms underlying the epigenetic modifications identified, to develop a predictive panel of lifestyle, environmental, genetic and epigenetic markers increasing susceptibility to incident T2D in South Asians, and to quantify the contribution of these risk factors to T2D amongst South Asians in diverse regional settings.
This research will improve understanding of epigenetic mechanisms underlying T2D, and may enable development of novel biomarkers and therapeutic strategies to reduce the burden of T2D amongst South Asians worldwide.'
Altri progetti dello stesso programma (FP7-HEALTH)
DECANBIO (2008)
Novel MS-based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer
Read MoreGENEGRAFT (2011)
Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector
Read MoreALPHA-MAN (2010)
Clinical development of Enzyme Replacement Therapy in alpha-Mannosidosis patients using recombinant human enzyme
Read More